CONFERENCE UPDATE: EULAR 2022
Bimekizumab improves outcomes in patients with active PsA and inadequate response to TNFis: the be complete study
29 Jul 2022
Related Articles
CONFERENCE UPDATE: EULAR 2022
Bimekizumab improves outcomes in patients with active PsA and inadequate response to TNFis: the be complete study